The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data
about
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malariaGenetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association studyMathematical Modelling to Guide Drug Development for Malaria EliminationGametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient dataArtemisinin-naphthoquine versus artemether-lumefantrine for uncomplicated malaria in Papua New Guinean children: an open-label randomized trialPerceived Benefits, Harms, and Views About How to Share Data Responsibly: A Qualitative Study of Experiences With and Attitudes Toward Data Sharing Among Research Staff and Community Representatives in ThailandThe effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient dataPopulation Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.The clinical impact of artemisinin resistance in Southeast Asia and the potential for future spread.Initiation of gametocytogenesis at very low parasite density in Plasmodium falciparum infection.Optimizing the programmatic deployment of the anti-malarials artemether-lumefantrine and dihydroartemisinin-piperaquine using pharmacological modelling.Intermittent preventive treatment for malaria among children in a refugee camp in Northern Uganda: lessons learned.Neuroauditory toxicity of artemisinin combination therapies-have safety concerns been addressed?Randomized comparison of the efficacies and tolerabilities of three artemisinin-based combination treatments for children with acute Plasmodium falciparum malaria in the Democratic Republic of the Congo.Cost-effectiveness of dihydroartemisinin-piperaquine compared with artemether-lumefantrine for treating uncomplicated malaria in children at a district hospital in Tanzania.Effect of coadministered fat on the tolerability, safety, and pharmacokinetic properties of dihydroartemisinin-piperaquine in Papua New Guinean children with uncomplicated malaria.Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate dispersible tablets in paediatric patients with acute uncomplicated Plasmodium falciparum malaria: a phase II, multicentric, open-label study.Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.Artemisinin combination therapy: a good antimalarial, but is the dose right?Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data.Maximizing antimalarial efficacy and the importance of dosing strategies.Malaria eradication and elimination: views on how to translate a vision into realityRandomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina FasoRethinking Dosing Regimen Selection of Piperaquine for Malaria Chemoprevention: A Simulation Study.Altering Antimalarial Drug Regimens May Dramatically Enhance and Restore Drug Effectiveness.Chloroquine efficacy for Plasmodium vivax malaria treatment in southern EthiopiaCharacterization of the infectious reservoir of malaria with an agent-based model calibrated to age-stratified parasite densities and infectiousnessTreatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim(®)) in the treatment of uncomplicated malaria at public health facilities in four African countries.Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia.Failure of dihydroartemisinin plus piperaquine treatment of falciparum malaria by under-dosing in an overweight patient.Development of drugs for severe malaria in children.Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to quantify prevailing malaria drug-resistance genotypes.Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria.Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015.Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials.Historical review: does stress provoke Plasmodium falciparum recrudescence?Systematic review of clinical trials assessing the therapeutic efficacy of visceral leishmaniasis treatments: A first step to assess the feasibility of establishing an individual patient data sharing platform.Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow.
P2860
Q24201077-CD2219CD-4159-405B-83A9-CD2818380C2BQ27861941-961C506C-6DC9-4558-938D-790A920E7B0EQ28067367-0756A43B-266A-4B72-B50C-56714DAEDB8DQ28068072-05B8F728-A32A-4724-A0E3-E170CDE72510Q28542921-738C7E7B-66CA-442F-929D-82053344D3D3Q28608554-D7040F55-7AB8-4B62-8348-F9BD62433F8AQ30936416-E59721C6-C5AA-4B05-907D-5392D8106ED0Q31153944-BE632ED9-29BC-4ED4-9CE4-036F10AB6ED5Q33601837-81E8C9F5-C935-4E55-A3AE-72DDFE11BFBFQ33655603-8EE2C155-D881-4FD6-A753-233E254FD2BCQ33662226-179D2049-CA8C-44A3-9045-9275E37BB5CEQ33678483-F1223F11-9AAB-491A-85C1-B2EEF308DB39Q33721927-105BB94E-A0C4-4F72-8AFE-8E6CF54DD730Q33841142-B3927A26-F3E9-49F7-A85B-0E7AC6CF59BFQ34057403-EF259ED8-8270-4CFB-8C1C-A1F58A72CE6EQ34227179-339B2563-0C62-4B34-AD08-285F1267D3D5Q34299178-22C8F6F7-2AC7-478E-8A27-DB2A5DB84DC5Q34503134-BF8BB423-0F24-43BE-8969-39AA089B8ACAQ34677891-C650DA33-E737-46D1-AD7C-930FD8C15DD2Q35069127-AE2CA974-50A1-432A-A289-F170540BF087Q35224221-6A2DCE05-8963-40A6-AA90-763C8BAF91B5Q35580908-0431C88E-62AA-4A8F-99FC-3E3736B0B434Q35588265-06742391-1741-4427-894F-CD6B67674313Q35712522-88B5DF05-F85D-4F73-A836-C88567F3FA3AQ35859844-A6236C0E-F5E5-4F1D-927B-9C1263A14715Q36018444-01A10038-993A-4BD5-BE68-A29D0CCDEC44Q36075783-DCF85DFA-AAA7-4E5C-AF7E-B4A1EF0D9F12Q36402050-413BB24B-E152-4461-A6AE-7168E0B7D472Q36433138-33785581-A2FA-4A6E-BD6B-9D1A4188CB4FQ36508726-B089E9FD-CA54-49F7-AB6C-A64AA4CCBCC5Q37003081-B28F5693-E5C3-4F1F-9F94-AA5CFAB7203AQ37267688-46405BFE-1E6B-40E4-8F69-18B391AC50B7Q37291600-705269DB-E875-41DD-A5BB-F61757ED42CBQ37332190-7E65E319-D106-4892-9F86-726BCC1CDBEBQ37383670-A761300F-B403-4A9E-B950-3F23DE740B42Q37623024-88F4C12D-80B9-4329-92DF-ECBA3EE377ABQ38225084-3CF7EC87-A4A5-4F60-8DBC-4CE024280B1CQ38445667-9AD1B0DF-819E-4A40-85F8-C2F466D8D56EQ38926936-7EDE6ACC-99F8-485D-AE66-93F24A071B80Q39081800-C366D413-EA5C-42E5-9EAA-72EEB0F79981
P2860
The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient data
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The effect of dosing regimens ...... sis of individual patient data
@ast
The effect of dosing regimens ...... sis of individual patient data
@en
The effect of dosing regimens ...... sis of individual patient data
@nl
type
label
The effect of dosing regimens ...... sis of individual patient data
@ast
The effect of dosing regimens ...... sis of individual patient data
@en
The effect of dosing regimens ...... sis of individual patient data
@nl
prefLabel
The effect of dosing regimens ...... sis of individual patient data
@ast
The effect of dosing regimens ...... sis of individual patient data
@en
The effect of dosing regimens ...... sis of individual patient data
@nl
P2860
P921
P3181
P1433
P1476
The effect of dosing regimens ...... sis of individual patient data
@en
P2860
P304
e1001564; discussion e1001564
P3181
P356
10.1371/JOURNAL.PMED.1001564
P407
P577
2013-12-01T00:00:00Z